Scientists at the University of Southampton have made a significant discovery in efforts to develop a vaccine against Zika, dengue and Hepatitis C viruses that affect millions of people around the world.
In a study published in Science Immunology, researchers have shown that natural killer cells (NK cells), which are a fundamental part of the body’s immune system, can recognise many different viruses including global pathogens such as Zika, dengue and Hepatitis C viruses, through a single receptor called KIR2DS2.
Lead researcher Salim Khakoo, Professor of Hepatology, said the findings are very exciting and could change the way viruses are targeted by vaccines but warned that the research is still at an early stage, and animal studies/clinical trials will be needed to test the findings.
Vaccines work by stimulating the immune response to the coat of proteins on the virus enabling the body to fight off the virus and recognise it in the future. However, the viruses are able to change their coat proteins, helping the virus to evade the antibodies, meaning some viruses can be very hard to vaccinate against.
The Southampton team have shown that this NK cell receptor is able to target a non-variable part of the virus called the NS3 helicase protein, which is essential in making the virus work properly. Unlike other proteins, the NS3 helicase protein does not change, which allows the immune system to grab hold of it and let the NK cells deal with the threat.
Professor Khakoo said: “The NS3 helicase protein could be the key in unlocking the defence of lethal viruses that affect so many people around the world. It is very exciting to discover that other viruses similar to Hepatitis C, such as Zika virus, dengue virus, yellow fever virus, Japanese encephalitis virus and in fact all flaviviruses, contain a region within their NS3 helicase proteins that is recognised by exactly the same KIR2DS2 receptor. We believe that by targeting this NS3 helicase region, we could make a new type of vaccine based upon natural killer cells, which can be used to help protect people from these infections.”
The study, which was funded by the Wellcome Trust and the Medical Research Council, analysed DNA from more than 300 patients exposed to the Hepatitis C virus, which showed that the KIR2DS2 receptor was associated with successfully clearing the virus. The team then identified that the immune system targeted the NS3 helicase protein of this using the receptor and found that it prevented the virus multiplying.
They went on to demonstrate that this same mechanism icould be important for many different viruses for example the Zika and dengue viruses, which also contain a region within their NS3 helicase protein that is recognised by the KIR2DS2 receptor.
The researchers now need to determine whether these KIR2DS2+ NK cells are protective during acute flaviviral infections, and are hoping to develop a vaccine that targets natural killer cells. They believe that a similar process could be used to target cancer.
Professor Khakoo added: “Cancer treatments that use the body’s own immune system are becoming more common. Our findings present a completely new strategy for virus therapeutics which could be easily translated into the field of cancer. The next few years are going to be very exciting in this field.”
The Latest on: Vaccine for viruses
Is a universal flu vaccine possible? Bend biotechnology firm joins effort to create one
on August 16, 2018 at 2:13 pm
Grace Bio-Labs, a Bend-based life science research company, has received a federal contract to develop a screening tool that could help speed the development of a universal flu vaccine. The company wi... […]
$36 million grant to fund development of vaccine for Lassa virus in Baltimore
on August 16, 2018 at 9:20 am
Two Baltimore firms will work to develop and manufacture a vaccine for the Lassa virus, a deadly emerging threat in Africa, under a $36 million grant from a global disease preparedness organization. T... […]
Pfizer, BioNTech in $425 Million Flu Vaccine Collaboration
on August 16, 2018 at 7:57 am
Sign in or subscribe for access to peerless insight & analysis, curated data & interactives, and networking events. […]
First human trial of Zika vaccine gets underway
on August 16, 2018 at 7:26 am
RELATED Flea fighters may stem spread of diseases like Zika No licensed vaccines for Zika virus infection are available, although several are in development. The virus, manufactured by Charles River L... […]
NIH begins clinical trial of live, attenuated Zika vaccine
on August 16, 2018 at 6:42 am
Vaccinations have begun in a first-in-human trial of an experimental live, attenuated Zika virus vaccine developed by scientists at the National Institute of Allergy and Infectious Diseases (NIAID), p... […]
First Participant Enrolled in BiondVax's Universal Flu Vaccine Pivotal Phase 3 Clinical Trial
on August 16, 2018 at 4:57 am
NESS ZIONA, Israel, Aug. 8, 2018 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. BVXV, -3.45% reported today the first participant's initial visit in a pivotal clinical efficacy Phase 3 trial of the M-0... […]
CEPI Awards Contract Worth up to $36 million to Profectus BioSciences and Emergent BioSolutions to Develop Lassa Virus Vaccine
on August 16, 2018 at 3:35 am
OSLO, Norway, BALTIMORE and GAITHERSBURG, Md., Aug. 16, 2018 (GLOBE NEWSWIRE) -- CEPI (the Coalition for Epidemic Preparedness Innovations) today announced a new collaboration with Profectus BioScienc... […]
BioNTech Signs Collaboration Agreement with Pfizer to Develop mRNA-based Vaccines for Prevention of Influenza
on August 16, 2018 at 3:00 am
Under the terms of the agreement, BioNTech and Pfizer will jointly conduct research and development activities to help advance mRNA-based flu vaccines. Pfizer will assume sole responsibility for furth... […]
Pfizer bets on biotech flu vaccine in $425 million BioNTech alliance
on August 16, 2018 at 2:32 am
FRANKFURT (Reuters) - Pfizer has agreed to pay German biotech firm BioNTech up to $425 million in an alliance to develop more effective influenza jabs, the latest among several major pharma companies ... […]
Measles Cases Have Parents Seeking Vaccine Protection
on August 15, 2018 at 11:41 pm
“If you’ve received two doses of the vaccine you’re 98 percent protected most likely for your life,” he said. “If you’ve been in a room where someone had the virus, even two hours later, you can catch ... […]
via Google News and Bing News